Evidence map›Paper›PMID 34635081›Full record

ArticleBMC cancer2021

Clinicopathological features and outcomes in gastric-type of HPV-independent endocervical adenocarcinomas.

Lili Chen, Yizhen Niu, Xiaoyun Wan, Lina Yu, Xiaofei Zhang, Amanda Louise Strickland, Liya Dong, Feng Zhou, Weiguo Lu

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05259540 (Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05259540 phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma: A Phase II Single-arm Clinical Study

TypeinterventionalSponsorWomen's Hospital School Of Medicine Zhejiang UniversityRan2023 to 2025Enrolled42ConditionsCervical CancerArmscompound kushen injection combined with pabolizumab
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Lili Chen *Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yizhen Niu *Women's Reproductive Health Research Laboratory of Zhejiang Province, Women's Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.
Xiaoyun WanDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Lina YuDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Xiaofei ZhangDepartment of Pathology, Women's Hospital, School of Medicine, Zhejiang University, Province, Zhejiang, Hangzhou, China.
Amanda Louise StricklandDepartment of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
Liya DongDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Feng ZhouDepartment of Pathology, Women's Hospital, School of Medicine, Zhejiang University, Province, Zhejiang, Hangzhou, China. fungchew@zju.edu.cn.
Weiguo LuWomen's Reproductive Health Research Laboratory of Zhejiang Province, Women's Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China. lbwg@zju.edu.cn.
Women's Hospital, School of Medicine, Zhejiang University · CNNorthwestern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to analyze the clinicopathological features and outcomes of patients with gastric-type of HPV-independent endocervical adenocarcinoma (GAS HPVI ECA), and compare them with non-GAS HPVI ECA cases.

methodsThirty-eight GASs [including 17 minimal deviation adenocarcinoma (MDA), 21 non-MDA GAS] and 17 non-GAS HPVI ECAs were studied. Data of clinical features, pathological characteristics, treatment, and outcomes were evaluated.

resultsThe median age of patients with GAS and non-GAS HPVI ECA was 46 and 48 years, respectively (p = 0.93). Compared with non-GAS HPVI ECAs, GAS had more common complains of vaginal watery discharge (p = 0.04). GAS cases were also associated with higher clinical stage (p = 0.036), more common in deeper cervical stromal invasion (p = 0.002) and lymphoavascular invasion (p = 0.044). GAS was associated with worse median progression-free survival (PFS) (p = 0.02) and median overall survival (OS) (p = 0.03) over patients with non-GAS HPVI ECAs. MDA had similar clinical and pathological features and prognosis compared with non-MDA GAS. Of note, serum CA19-9 levels were significantly higher in GAS than that in non-GAS HPVI ECA cases.

conclusionsGAS cases were more likely to have high risk pathological factors and poorer PFS and OS compared with non-GAS HPVI ECAs. Serum CA19-9 may be helpful for diagnosis and screening in patients with GAS.

Indexed as

AdenocarcinomaAdultAgedCA-19-9 AntigenFemaleHumansMiddle AgedNeoplasm StagingPapillomavirus InfectionsPrognosisProgression-Free SurvivalRetrospective StudiesRisk FactorsUterine Cervical NeoplasmsVaginal DischargeCA-19-9 AntigenClinicopathological featuresGastric-typeHPV-independent endocervical adenocarcinoma (HPVI ECA)Serum CA19–9

Identifiers

PMID34635081
PMCPMC8507215
OpenAlexW3206699919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.